Molecular imaging agents for detection of β-amyloid plaques in Alzheimer’s disease
DOI:
https://doi.org/10.25758/set.634Keywords:
Alzheimer's disease, β-Amyloid aggregation, Molecular imaging, Molecular probesAbstract
The formation of amyloid structures is a neuropathological feature that characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s disease. Up to now, the definitive diagnostic of these diseases can only be accomplished by immunostaining of post-mortem brain tissues with dyes such as Thioflavin T and congo red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid radioprobes have been developed for β-amyloid imaging by positron emission tomography (PET) and single-photon emitted computed tomography (SPECT). The aim of this paper is to present a perspective of the available amyloid imaging agents, special those that have been selected for clinical trials and are at the different stages of US Food and Drugs Administration (FDA) approval.
Downloads
References
Alzheimer Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8(2):131-68.
Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100 (21):12462-7.
Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med. 2008;14(7-8): 451-64.
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735-41.
Ono M. Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains. Chem Pharm Bull. 2009;57(10):1029-39.
Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol. 2007;34(7):809-22.
Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem. 2010;53(3):933-41.
Ribeiro Morais G, Vicente Miranda H, Santos IC, Santos I, Outeiro TF, Paulo A. Synthesis and in vitro evaluation of fluorinated styryl benzazoles as amyloid-probes. Bioorg Med Chem. 2011;19(24):7698-710.
Ribeiro Morais G, Paulo A, Santos I. A synthetic overview of radiolabeled compounds forβ-amyloid targeting. Eur J Org Chem. 2012;2012 (7):1279-93.
Zhuang ZP, Kung MP, Wilson A, Lee CW, Plössl K, Hou C, et al. Structure-activity relationship of imidazo[1,2-alpha]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem. 2003;46(2):237-43.
Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging. 2004;31(8):1136-45.
Newberg AB, Wintering NA, Plössl K, Hochold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med. 2006;47(5):748-54.
Barrio J, Huang S, Cole G, Satyamurthy N. PET imaging of tangles and plaques in Alzheimer's disease with a highly hydrophobic probes. J Labelled Comp Radiopharm. 1999; 42(Suppl 11):S194-S5.
Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21(24):RC189.
Mathis CA, Wang YM, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of C-11-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003; 46(13):2740-54.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19.
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-25.
Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172(2):277-82.
Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh compound-B. Alzheimer Dis Assoc Disord. 2008;22(3):261-8.
Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an C-11-PIB positron emission tomography study. Ann Neurol. 2006;60(1):145-7.
Ikonomovic M, Price J, Abrahamson E, Mathis C, Paljug W, Debnath M, et al. Direct correlations of [H-3]flutemetamol binding with [H-3]PiB binding and amyloid-beta concentration and plaque load in [C-11]PiB imaged brains. Neurology. 2012;78(Meeting Abstracts 1):S34.002.
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-29.
Wolk D, Gomez J, Sadowsky C, Singh U, Rinne J, Wong D, et al. Brain autopsy and in-vivo cortical brain biopsy trials show a strong concordance between [F-18]flutemetamol PET and amyloid-beta pathology. Neurology. 2012;79(11):E88.
Express Healthcare. US FDA, EMEA accept GE healthcare's review applications for [18F] flutemetanol [Internet]. Express Healthcare; 2013 Jan 9. Available from: http://healthcare.financialexpress.com/latest-updates/1166-us-fda-emea-accept-ge-healthcare-s-review-applications-for-18f-flutemetamol
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-35.
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-83.
Fowler K, McConathy J, Khanna G, Dehdashti F, Benzinger TL, Miller-Thomas M, et al. Simultaneous PET/MRI acquisition: clinical potential in anatomically focused and whole-body examinations. Appl Radiol. 2013;42(6):9-14.
Yang L, Rieves D, Ganley C. Brain amyloid imaging - FDA approval of Florbetapir F18 Injection. New Engl J Med. 2012;367(10):885-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Saúde e Tecnologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.
The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).
All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.
